gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 01 Jul 2015.

Leucine-rich repeat kinase 2

LRRK2, leucine-rich repeat kinase 2, PARK8
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: AGE, CAN, E3 ubiquitin ligase, PINK1, HAD
Papers using LRRK2 antibodies
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Supplier
Lightowlers Bob, In PLoS ONE, 2009
... For LRRK2, rabbit monoclonal MJFF2 (Epitomics – see ...
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
Supplier
Kahle Philipp J., In PLoS ONE, 2009
... ReagentsAll cell culture media and supplements, BacMam LRRK2-GFP reagents, PrestoBlue™ cell viability assay reagent, Western blotting reagents and human neural stem cells were obtained from Life Technologies (Carlsbad, CA) ...
Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors
Supplier
Xia Xu-Gang et al., In International Journal of Biological Sciences, 2008
... LRRK2 and tTA transgenic rats were produced by ...
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.
Supplier
Feany Mel B., In PLoS ONE, 2007
... Full length WT-LRRK2 pCMV6-XL5 was purchased from Origene (NM_198578.2) ...
Tyramine and octopamine independently inhibit serotonin-stimulated aversive behaviors in Caenorhabditis elegans through two novel amine receptors.
Supplier
Hart Anne C., In PLoS ONE, 2006
... driven WT or mutant LRRK2 constructs, were injected with the co-injection marker, promoter of nmr-1 driven YFP2 [55], into transgenic wild type nematode lines ...
more suppliers
Papers on LRRK2
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
New
Giasson et al., Jacksonville, United States. In J Neurosci Res, 30 Jul 2015
Some PD patients with mutations in the leucine-rich repeat kinase 2 (LRRK2) gene exhibit tau pathology.
Selective Expression of Parkinson's disease-related Leucine-rich Repeat Kinase 2 G2019S Missense Mutation in Midbrain Dopaminergic Neurons Impairs Dopamine Release and Dopaminergic Gene Expression.
New
Cai et al., Chicago, United States. In Hum Mol Genet, 29 Jul 2015
While the Leucine-rich repeat kinase 2 (LRRK2) G2019S missense mutation (LRRK2 G2019S) is the most common causative genetic factor linked to PD, the effects of LRRK2 G2019S on the function and survival of SNpc DA neurons are poorly understood.
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
New
Zhang et al., New York City, United States. In Brain, 27 Jul 2015
Participants were recruited from Columbia University, New York, and fully sequenced for GBA mutations and genotyped for the LRRK2 G2019S mutation, the most common autosomal dominant mutation in the Ashkenazi Jewish population.
Pathways to Parkinsonism Redux: Convergent pathobiological mechanisms in genetics of Parkinson's disease.
Review
New
Cookson et al., Bethesda, United States. In Hum Mol Genet, 22 Jul 2015
Here we will focus on those genes nominated by genome-wide association studies (GWAS) in sporadic PD, with a particular emphasis on genes that overlap between familial and sporadic disease such as those encoding a-synuclein (SNCA), tau (MAPT) and leucine-rich repeat kinase 2 (LRRK2).
LRRK2 Pharmacological Inhibition Abates α-Synuclein Induced Neurodegeneration.
New
West et al., Birmingham, United States. In J Biol Chem, 15 Jul 2015
Genetic and biochemical studies implicate α-synuclein and leucine-rich repeat kinase 2 (LRRK2) in late-onset PD.
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease.
Review
New
Wade-Martins et al., Montréal, Canada. In Trends Biochem Sci, Apr 2015
In addition, increasing evidence implicates other PD-associated proteins such as α-synuclein (α-syn) and leucine-rich repeat kinase 2 (LRRK2) in mitochondrial dysfunction in genetic cases of PD with the potential for a large functional overlap with sporadic disease.
The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin.
New
Mieyal et al., Cleveland, United States. In Ther Targets Neurol Dis, Dec 2014
Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with autosomal dominant PD, and several of these mutations have also been shown to increase the levels of reactive oxygen species in cells.
Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.
Review
New
Hashimoto et al., Tokyo, Japan. In Biomolecules, Dec 2014
However, other pathological features, such as abnormal mitochondria, enhanced oxidative stress and LRRK2 accumulation, were observed in the αS-globules, but not in the βS-globules.
The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.
Review
New
Ichikawa et al., Sagamihara, Japan. In Parkinsons Dis, Dec 2014
In this review, we discuss the physiological role of α-synuclein and LRRK2 in the abnormal phosphorylation of tau.
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.
New
Impact
Dawson et al., Baltimore, United States. In Cell, May 2014
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and sporadic Parkinson's disease (PD).
Multiplying messages LRRK beneath Parkinson disease.
New
Impact
Guo et al., Ann Arbor, United States. In Cell, May 2014
link PD protein leucine-rich repeat kinase 2 (LRRK2) to abnormalities of translational control, a pathogenic mechanism implicated in an increasing number of CNS neurodegenerative diseases, as well as in normal aging.
[Molecular basis of Parkinson's disease linked with mutations in the LRRK2 gene].
Review
Usenko et al., In Mol Biol (mosk), 2014
Despite of the fact that mutations in the leucine-rich repeat kinase (LRRK2) gene are the most common cause of inherited forms of PD known today, the mechanisms by which mutations in the LRRK2 gene lead to disease remain unclear.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
Impact
Sterneckert et al., Germany. In Cell Stem Cell, 2013
The LRRK2 mutation G2019S is the most common genetic cause of Parkinson's disease (PD).
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
Impact
Izpisua Belmonte et al., Beijing, China. In Nature, 2012
We decided to evaluate nuclear organization in the context of ageing-associated disorders by focusing on a leucine-rich repeat kinase 2 (LRRK2) dominant mutation (G2019S; glycine-to-serine substitution at amino acid 2019), which is associated with familial and sporadic Parkinson's disease as well as impairment of adult neurogenesis in mice.
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
GeneRIF
Molnár et al., Budapest, Hungary. In Ideggyogy Sz, 2012
Data suggest that the mutation LRRK2 G2019S may be a rare cause of Parkinson disease in the Hungarian population.
Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.
GeneRIF
Kortholt et al., Groningen, Netherlands. In Proc Natl Acad Sci U S A, 2012
data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity
Number and brightness analysis of LRRK2 oligomerization in live cells.
GeneRIF
Jameson et al., Honolulu, United States. In Biophys J, 2012
results show, for the first time to our knowledge, that LRRK2 is predominantly monomeric throughout the cytosol of living cells, but attains predominately higher oligomeric states in the plasma membrane
GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.
GeneRIF
Chen et al., Shanghai, China. In Front Biosci (elite Ed), 2011
results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells
Evaluation of the role of LRRK2 gene in Parkinson's disease in an East Indian cohort.
GeneRIF
Ray et al., Calcutta, India. In Dis Markers, 2011
LRRK2 has minimal role as a candidate and susceptibility gene in Parkinson's disease pathogenesis among East Indians.
Pathological roles of α-synuclein in neurological disorders.
Review
Impact
Stefanis et al., Athens, Greece. In Lancet Neurol, 2011
α-Synuclein also seems to be linked to other genetic forms of Parkinson's disease, such as those linked to mutations in GBA or LRRK2, possibly through common effects on autophagy and lysosomal function.
More papers using LRRK2 antibodies
Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase.
Supplier
Kahle Philipp J., In PLoS ONE, 1991
... The DR4A/3EDD anti-LRRK2-kinase domain antibody is described in reference [35] and goat polyclonal anti 14-3-3 antibody was purchased from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA, USA) ...
share on facebooktweetadd +1mail to friends